Literature DB >> 27174551

Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.

Anton Tomšič1, Mark A Schotborgh2, Johan S J Manshanden2, Wilson W L Li2, Bas A J M de Mol2.   

Abstract

OBJECTIVES: To evaluate the relationship between the timing of either ticagrelor or clopidogrel discontinuation and bleeding-related complications in patients undergoing isolated on-pump coronary artery bypass grafting (CABG).
METHODS: Between January 2012 and December 2014, 705 consecutive patients underwent isolated on-pump CABG at our institution. Of these, 626 were eligible for this study. Surgery under acetylsalicylic acid (ASA) was performed in 404 patients (ASA group) and 222 patients underwent surgery under dual antiplatelet treatment (DAPT). Patients exposed to DAPT were stratified into the following groups: ticagrelor within 72 h prior to surgery (Group T ≤ 72, n = 63); ticagrelor within 72-120 h prior to surgery (Group T72-120, n = 21); clopidogrel within 120 h prior to surgery (Group C ≤ 120, n = 125); clopidogrel within 120-168 h prior to surgery (Group C120-168, n = 13).
RESULTS: Transfusion requirements in Group T ≤ 72 (72.1 vs 41.3%, P < 0.001) and Group C ≤ 120 (71.2 vs 41.3%, P < 0.001) were significantly higher compared with the ASA group. Multivariable analysis, comparing Group C ≤ 120, C120-168, T ≤ 72 and T72-120 with the ASA group, revealed Group C ≤ 120 and Group T ≤ 72 as predictors of bleeding-related complications. No increased incidence of bleeding-related complications was seen when ticagrelor was discontinued >72 h or clopidogrel >120 h prior to surgery.
CONCLUSIONS: Ticagrelor discontinuation >72 h and clopidogrel discontinuation >120 h prior to surgery were not associated with an increased risk of bleeding-related complications. Based on these findings, a period of ticagrelor discontinuation shorter than advised by current international guidelines might be justifiable.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Antiplatelet drugs; Bleeding; Blood transfusion; Cardiac surgery; Coronary artery bypass grafting

Mesh:

Substances:

Year:  2016        PMID: 27174551     DOI: 10.1093/ejcts/ezw149

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.

Authors:  Sammer Diab; Shemy Carasso; Mattan Arazi; Leonid Sternik; Ehud Raanani; Erez Kachel; Liza Grosman-Rimon; Amjad Shalabi; Offer Amir
Journal:  J Cardiothorac Surg       Date:  2021-05-22       Impact factor: 1.637

2.  STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.

Authors:  Pierre Tibi; R Scott McClure; Jiapeng Huang; Robert A Baker; David Fitzgerald; C David Mazer; Marc Stone; Danny Chu; Alfred H Stammers; Tim Dickinson; Linda Shore-Lesserson; Victor Ferraris; Scott Firestone; Kalie Kissoon; Susan Moffatt-Bruce
Journal:  J Extra Corpor Technol       Date:  2021-06

3.  The impact of dual antiplatelet therapy administration on the risk of bleeding complications during coronary artery bypass surgery.

Authors:  Paolo Nardi; Calogera Pisano; Maria Turturici; Fabio Bertoldo; Vito Renato Maggio; Carlo Bassano; Dario Buioni; Antonio Scafuri; Claudia Altieri; Giovanni Ruvolo
Journal:  Kardiochir Torakochirurgia Pol       Date:  2021-10-05

4.  How do type of preoperative P2Y12 receptor inhibitor and withdrawal time affect bleeding? Protocol of a systematic review and individual patient data meta-analysis.

Authors:  Michael Schoerghuber; Gudrun Pregartner; Andrea Berghold; Ines Lindenau; Robert Zweiker; Andreas Voetsch; Elisabeth Mahla; Andreas Zirlik
Journal:  BMJ Open       Date:  2022-03-28       Impact factor: 2.692

Review 5.  Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.

Authors:  Marijana Matejic-Spasic; Kambiz Hassan; Matthias Thielmann; Stephan Geidel; Robert F Storey; Michael Schmoeckel; Harriet Adamson; Efthymios N Deliargyris; Daniel Wendt
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

6.  Impact of preoperative antithrombotic therapy in patients undergoing elective isolated coronary artery bypass grafting.

Authors:  Gijs J van Steenbergen; Albert H M van Straten; Serhat Kabak; Dennis van Veghel; Lukas Dekker; Mohamed A Soliman-Hamad
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-29

Review 7.  Ticagrelor - toward more efficient platelet inhibition and beyond.

Authors:  Michał J Kubisa; Mateusz P Jezewski; Aleksandra Gasecka; Jolanta M Siller-Matula; Marek Postuła
Journal:  Ther Clin Risk Manag       Date:  2018-01-17       Impact factor: 2.423

8.  A Difference in Bleeding and Use of Blood and Blood Products in Patients who Were Preoperatively on Aspirin or Dual Antiplatelet Therapy Before Coronary Artery Bypass Grafting.

Authors:  Slavenka Straus; Ilirijana Haxhibeqiri-Karabdic; Sanja Granov Grabovica; Nermir Granov
Journal:  Med Arch       Date:  2018-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.